116 related articles for article (PubMed ID: 37535333)
1. Physical and pharmacokinetic characterization of Soluvec™, a novel, solvent-free aqueous ivermectin formulation.
Mandalaywala R; Rana A; Ramos AL; Sampson P; Ashkenas J
Ther Deliv; 2023 Jun; 14(6):391-399. PubMed ID: 37535333
[TBL] [Abstract][Full Text] [Related]
2. Sustained release ivermectin-loaded solid lipid dispersion for subcutaneous delivery: in vitro and in vivo evaluation.
Lu M; Xiong D; Sun W; Yu T; Hu Z; Ding J; Cai Y; Yang S; Pan B
Drug Deliv; 2017 Nov; 24(1):622-631. PubMed ID: 28282989
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneously injected ivermectin-loaded mixed micelles: formulation, pharmacokinetics and local irritation study.
Dong J; Song X; Lian X; Fu Y; Gong T
Drug Deliv; 2016 Sep; 23(7):2220-2227. PubMed ID: 25188004
[TBL] [Abstract][Full Text] [Related]
4. Influence of levodropropizine and hydroxypropyl-β-cyclodextrin association on the physicochemical characteristics of levodropropizine loaded in hydroxypropyl-β-cyclodextrin microcontainers: Formulation and in vitro characterization.
Yousaf AM; Qadeer A; Raza SA; Chohan TA; Shahzad Y; Din FU; Khan IU; Hussain T; Alvi MN; Mahmood T
Polim Med; 2019; 49(1):35-43. PubMed ID: 31769938
[TBL] [Abstract][Full Text] [Related]
5. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
[TBL] [Abstract][Full Text] [Related]
6. Ivermectin disposition kinetics after subcutaneous and intramuscular administration of an oil-based formulation to cattle.
Lifschitz A; Virkel G; Pis A; Imperiale F; Sanchez S; Alvarez L; Kujanek R; Lanusse C
Vet Parasitol; 1999 Oct; 86(3):203-15. PubMed ID: 10511102
[TBL] [Abstract][Full Text] [Related]
7. Preparation of curcumin-hydroxypropyl-β-cyclodextrin inclusion complex by cosolvency-lyophilization procedure to enhance oral bioavailability of the drug.
Li N; Wang N; Wu T; Qiu C; Wang X; Jiang S; Zhang Z; Liu T; Wei C; Wang T
Drug Dev Ind Pharm; 2018 Dec; 44(12):1966-1974. PubMed ID: 30059244
[TBL] [Abstract][Full Text] [Related]
8. Enhanced oral bioavailability of koumine by complexation with hydroxypropyl-β-cyclodextrin: preparation, optimization,
Hu Q; Fu X; Su Y; Wang Y; Gao S; Wang X; Xu Y; Yu C
Drug Deliv; 2021 Dec; 28(1):2415-2426. PubMed ID: 34763595
[TBL] [Abstract][Full Text] [Related]
9. Comparative muscle irritation and pharmacokinetics of florfenicol-hydroxypropyl-β-cyclodextrin inclusion complex freeze-dried powder injection and florfenicol commercial injection in beagle dogs.
Fan G; Zhang L; Shen Y; Shu G; Yuan Z; Lin J; Zhang W; Peng G; Zhong Z; Yin L; Fu H
Sci Rep; 2019 Nov; 9(1):16739. PubMed ID: 31723173
[TBL] [Abstract][Full Text] [Related]
10. Binary inclusion complexes of diflunisal with β-cyclodextrin and hydroxypropyl-β-cyclodextrin: Preparation and characterization.
Bashir M; Syed HK; Asghar S; Irfan M; Aslam N; Iqbal MS; Khan IU; Shah PA; Khan NR; Ahmad J; Saleem M; Asif M
Pak J Pharm Sci; 2020 Sep; 33(5(Supplementary)):2307-2315. PubMed ID: 33832905
[TBL] [Abstract][Full Text] [Related]
11. Improvement in Solubility-Permeability Interplay of Psoralens from
Machado RD; Silva JCG; Silva LAD; Oliveira GAR; Lião LM; Lima EM; de Morais MC; da Conceição EC; Rezende KR
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889459
[TBL] [Abstract][Full Text] [Related]
12. A remodeled ivermectin polycaprolactone-based nanoparticles for inhalation as a promising treatment of pulmonary inflammatory diseases.
Mohammed SW; El-Megrab NA; Hasan AA; Gomaa E
Eur J Pharm Sci; 2024 Apr; 195():106714. PubMed ID: 38301972
[TBL] [Abstract][Full Text] [Related]
13. Field trial assessment of ivermectin pharmacokinetics and efficacy against susceptible and resistant nematode populations in cattle.
Canton C; Canton L; Domínguez MP; Moreno L; Lanusse C; Alvarez L; Ceballos L
Vet Parasitol; 2018 May; 256():43-49. PubMed ID: 29887029
[TBL] [Abstract][Full Text] [Related]
14. Liquiritin-Hydroxypropyl-Beta-Cyclodextrin Inclusion Complex: Preparation, Characterization, Bioavailability and Antitumor Activity Evaluation.
Wang Q; Zhang K; Weng W; Chen L; Wei C; Bao R; Adu-Frimpong M; Cao X; Yu Q; Shi F; Toreniyazov E; Ji H; Xu X; Yu J
J Pharm Sci; 2022 Jul; 111(7):2083-2092. PubMed ID: 35367247
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders.
Cutrignelli A; Sanarica F; Lopalco A; Lopedota A; Laquintana V; Franco M; Boccanegra B; Mantuano P; De Luca A; Denora N
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704045
[TBL] [Abstract][Full Text] [Related]
16. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization.
Camargo JA; Sapin A; Nouvel C; Daloz D; Leonard M; Bonneaux F; Six JL; Maincent P
Drug Dev Ind Pharm; 2013 Jan; 39(1):146-55. PubMed ID: 22397675
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Solubility and Stability of Aripiprazole in Binary and Ternary Inclusion Complexes Using Hydroxy Propyl Beta Cyclodextrin (HPβCD) and L-Arginine.
Awais S; Farooq N; Muhammad SA; El-Serehy HA; Ishtiaq F; Afridi M; Ahsan H; Ullah A; Nadeem T; Sultana K
Molecules; 2023 May; 28(9):. PubMed ID: 37175270
[TBL] [Abstract][Full Text] [Related]
18. Design of controlled-release formulation for ivermectin using silicone.
Maeda H; Brandon M; Sano A
Int J Pharm; 2003 Aug; 261(1-2):9-19. PubMed ID: 12878391
[TBL] [Abstract][Full Text] [Related]
19. Solubility Enhancement of Myricetin by Inclusion Complexation with Heptakis-
Han D; Han Z; Liu L; Wang Y; Xin S; Zhang H; Yu Z
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991574
[TBL] [Abstract][Full Text] [Related]
20. Ameliorating the antiparasitic activity of the multifaceted drug ivermectin through a polymer nanocapsule formulation.
de Souza ZC; Júnior FHX; Pinheiro IO; de Souza Rebouças J; de Abreu BO; Mesquita PRR; de Medeiros Rodrigues F; Quadros HC; Mendes TMF; Nguewa P; Allegretti SM; Farias LP; Formiga FR
Int J Pharm; 2023 May; 639():122965. PubMed ID: 37084836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
